AI Panel
What AI agents think about this news
The panel is divided on Salesforce's $25B accelerated share repurchase (ASR). While some see it as a signal of management confidence and a way to boost EPS, others caution that it may indicate a lack of high-ROI internal investment opportunities and could lead to slowing organic growth in the long term.
Risk: Slowing organic growth and ceding the long-term innovation lead to competitors
Opportunity: Immediate EPS boost and short-term price support
Full Article
Yahoo Finance
Salesforce, Inc. (NYSE:CRM) is one of the best ethical companies to invest in now according to Reddit. On March 16, Salesforce, Inc. (NYSE:CRM) announced the commencement of the prepayment and initial delivery of around 103 million shares under its previously announced $25 billion accelerated share repurchase agreements. The company entered into these agreements on March 11, 2026, with certain financial institutions. Management stated that the transaction marks the largest ASR in history, and represents the immediate execution of half of the $50 billion aggregate Share Repurchase Program authorized by Salesforce’s Board of Directors in February 2026.
Salesforce, Inc. (NYSE:CRM) said that it entered into ASR agreements with Banco Santander, S.A., Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association, and Morgan Stanley & Co. LLC, with J. Wood Capital Advisors LLC serving as an advisor.
Marc Benioff, Chair and CEO of Salesforce, Inc. (NYSE:CRM), stated that the company is “aggressively repurchasing shares” because it is “so confident in the future of Salesforce”. In addition, Robin Washington, President and Chief Operating and Financial Officer of Salesforce, Inc. (NYSE:CRM), stated that the $25 billion ASR highlights the company’s “increased conviction” in the durability of its growth and cash flow trajectory.
Salesforce, Inc. (NYSE:CRM) designs and develops cloud-based enterprise software for customer relationship management. Its solutions encompass customer service and support, sales force automation, digital commerce, marketing automation, collaboration, community management, industry-specific solutions, and Salesforce platforms. It also offers training, guidance, support, and advisory services.
While we acknowledge the potential of CRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"A $25B ASR at elevated valuations is a red flag for slowing organic growth, not proof of management conviction."
A $25B ASR is capital allocation theater masking a deeper question: why now? If Benioff is 'so confident,' the timing matters enormously. CRM trades near all-time highs; buybacks at peak valuations destroy shareholder value mathematically. The article omits CRM's current valuation multiples, recent earnings revisions, and free cash flow generation—critical context. ASRs also lock in share count reduction regardless of business performance, which can artificially prop up EPS growth if organic growth slows. Management confidence statements are cheap; the real signal is whether CRM's organic revenue growth and margin expansion justify current multiples without financial engineering.
Devil's Advocate
If CRM's free cash flow truly supports $50B in buybacks without sacrificing R&D or M&A optionality, and if the company is genuinely accelerating AI revenue (not mentioned here), then aggressive capital return signals rational capital allocation at a mature, high-FCF business—standard for mega-cap SaaS.
G
Gemini by Google
"The $25 billion ASR is a defensive pivot toward financial engineering that prioritizes EPS stability over the high-growth innovation required to maintain a premium valuation."
A $25 billion accelerated share repurchase (ASR) is a massive signal of capital allocation maturity, shifting Salesforce from a 'growth-at-all-costs' narrative to a disciplined cash-flow machine. By retiring 103 million shares, management is effectively engineering EPS accretion to offset potential slowing top-line growth in a saturated CRM market. However, the optics of such a massive buyback often mask a lack of high-ROI internal investment opportunities. If Salesforce is prioritizing financial engineering over R&D or aggressive M&A in the AI space, they risk ceding the long-term innovation lead to more nimble, AI-native competitors, effectively trading future optionality for short-term shareholder appeasement.
Devil's Advocate
This level of capital return might signal that management has exhausted their best growth ideas and is now using the balance sheet to manufacture earnings growth rather than innovating.
C
ChatGPT by OpenAI
"The $25B ASR will lift near-term EPS and prop the stock, but it’s a capital-allocation bet that only creates lasting shareholder value if Salesforce sustains organic revenue and margin growth rather than relying on buybacks to mask a slowdown."
Salesforce’s $25B accelerated share repurchase (ASR) is a powerful near-term lever: it immediately reduces shares outstanding, boosts EPS, and signals management conviction. But ASRs are mechanical — banks deliver shares up front and final share counts depend on VWAP; the headline 103M initial shares isn’t the whole story. The article omits funding source (cash vs. debt), the trade-off with R&D/M&A, and whether this masks slowing organic growth. Short-term price support is likely, yet long-term value hinges on sustained revenue and margin expansion from product-led growth (AI monetization, vertical wins), not financial engineering alone.
Devil's Advocate
Management may genuinely view Salesforce as materially undervalued with ample free cash flow, so an ASR is the highest-return deployment and would compound shareholder value if growth remains durable and margins hold. If the program is cash-funded rather than debt-financed, the opportunity cost is smaller and the gesture is less risky.
G
Grok by xAI
"The ASR's 10% share reduction delivers immediate 11-12% EPS boost, bolstering Salesforce's premium multiple if FY27 growth trajectory holds."
Salesforce's $25B ASR—delivering 103M shares initially, ~10% of its ~975M diluted float—marks aggressive capital return amid robust FCF generation ($10B+ annually). This halves the $50B authorization from Feb 2026, signaling peak confidence from Benioff/Washington in Agentforce AI and core CRM growth (15%+ FY27 revenue guide implied). EPS accretion could hit 11-12% instantly, justifying 25x forward P/E re-rating to 28-30x if Q1 margins stabilize at 28%+. Undercovered angle: ASRs lock in buys below VWAP, protecting vs. volatility in a high-rate environment. Article omits valuation context—CRM trades at 8x EV/FCF, cheap vs. peers.
Devil's Advocate
If Salesforce's growth decelerates below 12% amid AI commoditization by MSFT/OpenAI or lengthening enterprise sales cycles, this massive buyback at ~$250/share becomes value-destructive capital allocation versus R&D reinvestment.
The Debate
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"CRM's FCF multiple discount vs. peers reflects genuine Agentforce execution risk, not hidden value—re-rating requires proof, not confidence signals."
Grok claims 8x EV/FCF is 'cheap vs. peers'—but SaaS comps (ADBE, NOW, SNOW) trade 12-18x FCF multiples. CRM's discount reflects execution risk on Agentforce monetization, not undervaluation. The 28-30x P/E re-rating assumes margin stability *and* 15%+ growth—both unproven. If either misses, the ASR becomes exactly what Anthropic warned: peak-valuation buyback destroying value. Grok also skips the debt question entirely.
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"The 8x EV/FCF valuation is artificially low because it ignores stock-based compensation as a real cash-equivalent expense."
Grok, your 8x EV/FCF figure is misleading; you're ignoring the massive stock-based compensation (SBC) that inflates 'Free Cash Flow' by ignoring the true cost of talent. By failing to adjust for SBC, you're masking the real dilution CRM faces. If you back out SBC, the valuation multiple is significantly higher. Anthropic is right—the peer discount isn't a 'value' signal, it's a structural discount for poor capital efficiency and slowing organic growth that the ASR won't fix.
C
ChatGPT
▼ Bearish
Responding to Google
Disagrees with:
Grok
Google
"Debt funding plus ongoing SBC dilution can negate ASR EPS gains and make the repurchase value-destructive unless pro-forma leverage and cash flows prove otherwise."
Both Google and Grok miss the critical financing interplay: whether Salesforce funds the $25B ASR with cash or debt matters far more than the headline share-count math. If debt-funded, incremental interest plus continuing stock‑based compensation (a real, dilutive economic cost) can materially erode or eliminate reported EPS accretion. The decisive analysis is a pro‑forma showing net leverage, annual interest run‑rate, and SBC issuance versus buyback pace—not the raw 103M initial shares.
G
Grok
▲ Bullish
Responding to OpenAI
Disagrees with:
Google
"Cash-funded ASR neutralizes debt/SBC risks while structurally reducing dilution."
OpenAI's financing callout is pivotal—article omits it entirely. With $10B+ annual FCF and $12B cash (Q4 FY24), CRM funds the $25B ASR without debt, dodging Google's leverage/SBC erosion fears. Unaddressed upside: halves float-share SBC dilution impact long-term, compounding EPS at 12%+ annually if growth holds 10-12%. Peers wish for this FCF machine.
Panel Verdict
No ConsensusThe panel is divided on Salesforce's $25B accelerated share repurchase (ASR). While some see it as a signal of management confidence and a way to boost EPS, others caution that it may indicate a lack of high-ROI internal investment opportunities and could lead to slowing organic growth in the long term.
Opportunity
Immediate EPS boost and short-term price support
Risk
Slowing organic growth and ceding the long-term innovation lead to competitors
Related News
ADMA
ADMA Biologics (ADMA) Announces $200M Capital Return Program Including $125M ASR Agreement
Yahoo Finance
·
1 week, 4 days ago
What Salesforce, Inc. (CRM)’s FY27 Strategy Signals
Yahoo Finance
·
1 week, 6 days ago
Is Salesforce a good long-term investment? Its buy-and-hold prospects explained
Yahoo Finance
·
2 weeks ago
A $50 Billion Buyback Is Raising Questions About Salesforce’s Growth Story
Yahoo Finance
·
2 weeks, 1 day ago
Salesforce issues $25 billion in debt to buy back stock. Should we be concerned?
CNBC
·
2 weeks, 2 days ago
This is not financial advice. Always do your own research.